Compare Freshworks Inc (FRSH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Pfizer Inc — how do they compare? Freshworks Inc trades at $10.66 (market cap $2.93B), while Pfizer Inc trades at $25.2 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 48.3× Freshworks Inc's market cap, and Pfizer Inc pays a 6.93% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | PFE | |
|---|---|---|
Market Cap | $2.93B | $141.46B |
Sector | Technology | Health |
52-Week High | $14.77 | $28.56 |
52-Week Low | $6.88 | $23.29 |
Enterprise Value | $2.19B | $192.12B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.47, down 3.32% on the day, with a bullish technical signal from moving averages. The company shows a strong fundamental turnaround, achieving profitability in 2025 with a net income margin of 20.69% and robust revenue growth from $498M in 2022 to $839M in 2025. Recent news highlights a strategic pivot to its employee experience (EX) business and new AI product launches, with the Q2 2026 earnings report scheduled for August 4, 2026.
The outlook is positive, supported by a profitable growth trajectory, a 50% analyst buy rating, and a significant valuation discount to software peers. Key risks include execution of the EX pivot, competitive pressures in SaaS, and the need to sustain high gross margins. The stock offers opportunity as a value play with accelerating fundamentals, but faces typical growth stock volatility.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
